Trivant Custom Portfolio Group’s Edwards Lifesciences EW Stock Holding History

Trivant Custom Portfolio Group’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.01M	Buy	+11,181	New	+$937K	0.54%	54

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Trivant Custom Portfolio Group's EW Position: Q2 2026 in Review

Trivant Custom Portfolio Group opened a new position in Edwards Lifesciences (EW) in Q2 2026: 11,181 shares worth $1.01M. The stake represents 0.54% of the portfolio and ranks #54 among its holdings.

1,327 funds tracked by Wall St. Rank hold EW as of Q2 2026.

Trivant Custom Portfolio Group held 11,181 shares of Edwards Lifesciences worth $1.01M as of Q2 2026.
Edwards Lifesciences was a new Trivant Custom Portfolio Group position in Q2 2026.
Edwards Lifesciences made up 0.54% of Trivant Custom Portfolio Group's portfolio in Q2 2026, its #54 holding.
1,327 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Trivant Custom Portfolio Group's 13F filing for Q2 2026, filed 27 Jul 2026.